PHGDH and ovarian carcinoma: Other studies have identified new therapeutic targets for ovarian cancer that may address resistance to platinum agents or PARP inhibitors, such as phosphoglycerate dehydrogenase (PHGDH)173 and master regulators of mitochondria (PGC1α/β).176